5 results about "In vivo tests" patented technology

Provided herein are methods and compositions related to mice that express human or humanized Foot receptors (FcaR) from an FcaR locus positioned in the mouse leukocyte receptor complex (LRC). In certain embodiments, such mice are useful for in vivo testing of therapeutic agents comprising a human IgA Fc (e.g., the testing of the pharmacokinetic and / or pharmacodynamic properties of such therapeutic agents and dosing regimens). Also provided herein are methods of using such mice, cells from such mice, methods of making such mice, and ES cells comprising the same genetic modifications as such mice. Provided herein are methods and compositions related to mice that express human or humanized Foot receptors (FcaR) from an FcaR locus positioned in the mouse leukocyte receptor complex (LRC). In certain embodiments, such mice are useful for in vivo testing of therapeutic agents comprising a human IgA Fc (e.g., the testing of the pharmacokinetic and / or pharmacodynamic properties of such therapeutic agents and dosing regimens). Also provided herein are methods of using such mice, cells from such mice, methods of making such mice, and ES cells comprising the same genetic modifications as such mice.

An in-vivo testing device is disclosed for dynamically measuring the mechanical properties of skin. The device includes a horizontal reciprocating tensile stress-strain detection unit configured to contact the skin surface and acquire displacement and tensile force data, wherein the detection unit comprises at least two contact heads. A driving unit, equipped with a motor capable of outputting reciprocating linear motion perpendicular to the skin surface, is provided to drive the contact heads. A reversing unit converts the perpendicular reciprocating linear motion into a horizontal reciprocating tensile motion of the contact heads relative to the skin surface. The reversing unit includes at least one right-angle reversing lever connecting the driving unit and the detection unit. The disclosed device enables reliable evaluation of the dynamic viscoelastic properties of skin in a non-destructive manner, thereby providing accurate and repeatable characterization of skin biomechanics under in-vivo conditions.

The application discloses a kind of pharmaceutical compositions, it includes stilben compound and pharmaceutically acceptable adjuvant;Wherein, the stilben compound is Pterostilbene or its pharmaceutically acceptable salt, the pharmaceutically acceptable adjuvant includes glucosyl tangeritin and / or glycyrrhizic acid salt.The in vitro and / or in vivo test results show that the pharmaceutical composition provided by the application has good curative effect for preventing and / or treating drug-induced liver injury;Meanwhile, it can also significantly reduce serum transaminase level, alleviate the symptoms such as liver and spleen edema, and also has good inhibitory effect on proinflammatory cytokines.The test results further show that stilben compound and pharmaceutically acceptable adjuvant (including glucosyl tangeritin and / or glycyrrhizic acid salt) combination, good safety, and easy to dissolve, release and / or absorption etc., improve the bioavailability of Pterostilbene (PTE), have synergistic effect, and have good application prospect.

The application belongs to the field of medicine, and relates to a butyrylcholinesterase selective inhibitor and a preparation method and application thereof. The application provides a brand-new butyrylcholinesterase selective inhibitor skeleton, in-vitro verification shows that part of the compounds have extremely high butyrylcholinesterase inhibitory activity and selectivity, in-vivo testing finds that a representative compound has an obvious cognitive improvement effect on an AD mouse model, and the butyrylcholinesterase selective inhibitor provided by the application has the potential to be used as a drug for preventing or treating Alzheimer's disease.

Provided herein are methods and compositions related to mice that express human or humanized Foot receptors (FcaR) from an FcaR locus positioned in the mouse leukocyte receptor complex (LRC). In certain embodiments, such mice are useful for in vivo testing of therapeutic agents comprising a human IgA Fc (e.g., the testing of the pharmacokinetic and / or pharmacodynamic properties of such therapeutic agents and dosing regimens). Also provided herein are methods of using such mice, cells from such mice, methods of making such mice, and ES cells comprising the same genetic modifications as such mice. Provided herein are methods and compositions related to mice that express human or humanized Foot receptors (FcaR) from an FcaR locus positioned in the mouse leukocyte receptor complex (LRC). In certain embodiments, such mice are useful for in vivo testing of therapeutic agents comprising a human IgA Fc (e.g., the testing of the pharmacokinetic and / or pharmacodynamic properties of such therapeutic agents and dosing regimens). Also provided herein are methods of using such mice, cells from such mice, methods of making such mice, and ES cells comprising the same genetic modifications as such mice.